NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022

Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813–1826.

• PubMed
Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813–1826.16641398)| false
• Search Google Scholar
• Export Citation

Auletta JJ, Kou J, Chen M, Shaw BE. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides, 2021. Accessed January 5, 2023. Available at: https://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/Pages/index.aspx

Auletta JJ, Kou J, Chen M, Shaw BE. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides, 2021. Accessed January 5, 2023. Available at: https://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/Pages/index.aspx)| false
• Search Google Scholar
• Export Citation

Flannelly C, Tan BE, Tan JL, et al. Barriers to hematopoietic cell transplantation for adults in the United States: a systematic review with a focus on age. Biol Blood Marrow Transplant 2020;26:2335–2345.

• PubMed
Flannelly C, Tan BE, Tan JL, Barriers to hematopoietic cell transplantation for adults in the United States: a systematic review with a focus on age. Biol Blood Marrow Transplant 2020;26:2335–2345.32961375)| false
• Search Google Scholar
• Export Citation

Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015;21:1863–1869.

• PubMed
Majhail NS, Farnia SH, Carpenter PA, Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015;21:1863–1869.26256941)| false
• Search Google Scholar
• Export Citation

Hosing C. Hematopoietic stem cell mobilization with G-CSF. Methods Mol Biol 2012;904:37–47.

• PubMed
Hosing C. Hematopoietic stem cell mobilization with G-CSF. Methods Mol Biol 2012;904:37–47.22890920)| false
• Search Google Scholar
• Export Citation

Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175–181.

• PubMed
Bensinger WI, Martin PJ, Storer B, Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175–181.11172139)| false
• Search Google Scholar
• Export Citation

Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012;367:1487–1496.

• PubMed
Anasetti C, Logan BR, Lee SJ, Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012;367:1487–1496.23075175)| false
• Search Google Scholar
• Export Citation

Lee SJ, Logan B, Westervelt P, et al. Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation: long-term follow-up of a randomized clinical trial. JAMA Oncol 2016;2:1583–1589.

• PubMed
Lee SJ, Logan B, Westervelt P, Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation: long-term follow-up of a randomized clinical trial. JAMA Oncol 2016;2:1583–1589.27532508)| false
• Search Google Scholar
• Export Citation

Alousi A, Wang T, Hemmer MT, et al. Peripheral blood versus bone marrow from unrelated donors: bone marrow allografts have improved long-term overall and graft-versus-host disease-free, relapse-free survival. Biol Blood Marrow Transplant 2019;25:270–278.

• PubMed
Alousi A, Wang T, Hemmer MT, Peripheral blood versus bone marrow from unrelated donors: bone marrow allografts have improved long-term overall and graft-versus-host disease-free, relapse-free survival. Biol Blood Marrow Transplant 2019;25:270–278.30292009)| false
• Search Google Scholar
• Export Citation

Brunstein CG, Eapen M, Ahn KW, et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012;119:5591–5598.

• PubMed
Brunstein CG, Eapen M, Ahn KW, Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012;119:5591–5598.22496153)| false
• Search Google Scholar
• Export Citation

Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14:641–650.

• PubMed
Luznik L, O’Donnell PV, Symons HJ, HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14:641–650.18489989)| false
• Search Google Scholar
• Export Citation

Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009;15:1628–1633.

• PubMed
Bacigalupo A, Ballen K, Rizzo D, Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009;15:1628–1633.19896087)| false
• Search Google Scholar
• Export Citation

McCune JS, Quinones CM, Ritchie J, et al. Harmonization of Busulfan Plasma Exposure Unit (BPEU): a community-initiated consensus statement. Biol Blood Marrow Transplant 2019;25:1890–1897.

• PubMed
McCune JS, Quinones CM, Ritchie J, Harmonization of Busulfan Plasma Exposure Unit (BPEU): a community-initiated consensus statement. Biol Blood Marrow Transplant 2019;25:1890–1897.31136799)| false
• Search Google Scholar
• Export Citation

Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol 2014;32:3249–3256.

• PubMed
Sorror ML, Storb RF, Sandmaier BM, Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol 2014;32:3249–3256.25154831)| false
• Search Google Scholar
• Export Citation

Sorror ML. How I assess comorbidities before hematopoietic cell transplantation. Blood 2013;121:2854–2863.

Sorror ML. How I assess comorbidities before hematopoietic cell transplantation. Blood 2013;121:2854–2863.)| false
• Search Google Scholar
• Export Citation

Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. Biol Blood Marrow Transplant 2014;20:600–616.

• PubMed
Bubalo J, Carpenter PA, Majhail N, Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. Biol Blood Marrow Transplant 2014;20:600–616.24462742)| false
• Search Google Scholar
• Export Citation

Ijaz A, Khan AY, Malik SU, et al. Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant 2019;25:94–99.

• PubMed
Ijaz A, Khan AY, Malik SU, Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant 2019;25:94–99.30195074)| false
• Search Google Scholar
• Export Citation

Merryman RW, Kim HT, Zinzani PL, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/ refractory lymphoma. Blood 2017;129:1380–1388.

• PubMed
Merryman RW, Kim HT, Zinzani PL, Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/ refractory lymphoma. Blood 2017;129:1380–1388.28073785)| false
• Search Google Scholar
• Export Citation

Pidala J, Kim J, Jim H, et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica 2012;97:1882–1889.

Pidala J, Kim J, Jim H, A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica 2012;97:1882–1889.)| false
• Search Google Scholar
• Export Citation

Khimani F, Kim J, Chen L, et al. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. Bone Marrow Transplant 2017;52:1003–1009.

• PubMed
Khimani F, Kim J, Chen L, Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. Bone Marrow Transplant 2017;52:1003–1009.28368376)| false
• Search Google Scholar
• Export Citation

Maziarz RT, Diaz A, Miklos DB, et al. Perspective: an international fludarabine shortage: supply chain issues impacting transplantation and immune effector cell therapy delivery. Transplant Cell Ther 2022;28:723–726.

• PubMed
Maziarz RT, Diaz A, Miklos DB, Perspective: an international fludarabine shortage: supply chain issues impacting transplantation and immune effector cell therapy delivery. Transplant Cell Ther 2022;28:723–726.35940526)| false
• Search Google Scholar
• Export Citation

Chevallier P, Peterlin P, Garnier A, et al. Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies. Oncotarget 2018;9:33528–33535.

• PubMed
Chevallier P, Peterlin P, Garnier A, Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies. Oncotarget 2018;9:33528–33535.30323896)| false
• Search Google Scholar
• Export Citation

Saito T, Kanda Y, Kami M, et al. Therapeutic potential of a reduced- intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. Clin Cancer Res 2002;8:1014–1020.

• PubMed
Saito T, Kanda Y, Kami M, Therapeutic potential of a reduced- intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. Clin Cancer Res 2002;8:1014–1020.11948108)| false
• Search Google Scholar
• Export Citation

Saito T, Kanda Y, Nakai K, et al. Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation. Bone Marrow Transplant 2003;32:601–608.

• PubMed
Saito T, Kanda Y, Nakai K, Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation. Bone Marrow Transplant 2003;32:601–608.12953133)| false
• Search Google Scholar
• Export Citation

Markova M, Barker JN, Miller JS, et al. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant 2007;39:193–199.

• PubMed
Markova M, Barker JN, Miller JS, Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant 2007;39:193–199.17220905)| false
• Search Google Scholar
• Export Citation

Dimitrova D, Gea-Banacloche J, Steinberg SM, et al. Prospective study of a novel, radiation-free, reduced-intensity bone marrow transplantation platform for primary immunodeficiency diseases. Biol Blood Marrow Transplant 2020;26:94–106.

• PubMed
Dimitrova D, Gea-Banacloche J, Steinberg SM, Prospective study of a novel, radiation-free, reduced-intensity bone marrow transplantation platform for primary immunodeficiency diseases. Biol Blood Marrow Transplant 2020;26:94–106.31493539)| false
• Search Google Scholar
• Export Citation

Gvajaia A, Langston A, Esiashvil N, et al. Pentostatin/TBI conditioning is well-tolerated and permits engraftment of a second allogeneic stem cell transplant following primary or secondary rejection of an allogeneic hematopoietic stem graft. Blood 2019;134(Suppl 1):Abstract 5657.

Gvajaia A, Langston A, Esiashvil N, Pentostatin/TBI conditioning is well-tolerated and permits engraftment of a second allogeneic stem cell transplant following primary or secondary rejection of an allogeneic hematopoietic stem graft. Blood 2019;134(Suppl 1):Abstract 5657.)| false
• Search Google Scholar
• Export Citation